Innovation Pharmaceuticals announced that new Brilacidin antiviral data, based on research conducted by George Mason University (GMU)/National Center for Biodefense and Infectious Diseases researchers, was presented on July 21, 2021, at the American Society of Virology’s 40th Annual Meeting (ASV 2021). New antiviral data included Brilacidin’s inhibition of SARS-CoV-2 in additional cell lines (Caco-2, primary lung fibroblasts), and Brilacidin’s inhibition of alphaviruses—Venezuelan Equine Encephalitis Virus, Eastern Equine Encephalitis Virus—and Rift Valley Fever Virus, a bunyavirus. Brilacidin is the only non-peptidic defensin-mimetic drug candidate currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19 (NCT04784897). Innovation Pharma is developing Brilacidin for treatment of COVID-19 under U.S. FDA Fast Track designation. Brilacidin has shown potent and consistent inhibition in vitro against coronaviruses, alphaviruses and bunyaviruses (with laboratory testing against other viruses also underway), supporting Brilacidin’s potential to be developed as a broad-spectrum antiviral. The annual global antiviral drug market is estimated to reach $44 billion by 2026.